• Explore /
  • Poster
  • / CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).

CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

Axel Grothey

Axel Grothey

Mayo Clinic Cancer Center, Rochester, MN

Axel Grothey , Manish A. Shah , Takayuki Yoshino , Eric Van Cutsem , Julien Taieb , Ruihua Xu , Niall C. Tebbutt , Alfredo Falcone , Andres Cervantes , Laura Borodyansky , Chiang Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02753127

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS3619)

DOI

10.1200/JCO.2017.35.15_suppl.TPS3619

Abstract #

TPS3619

Poster Bd #

241b

Abstract Disclosures

Similar Posters

First Author: Sun Young Kim

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg

First Author: Johanna C. Bendell